drugset / Trial / NCT02234362

Vortioxetine for Menopausal Depression

NCT02234362

NaSingle-groupOpen-labelTreatment

Summary

The broad goal of this study was to examine the efficacy and tolerability of vortioxetine (flexible dose) for the treatment of major depressive disorder (MDD) in symptomatic women around the menopausal transition. We hypothesized that an eight-week treatment with vortioxetine would promote a significant improvement of depression symptoms and other menopause-related physical symptoms.

Timeline

Start
2015-06-12
Primary completion
2016-09-29
Completion
2016-09-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 10 mg
Subject Vortioxetine Unknown 15 mg
Subject Vortioxetine Unknown 20 mg